NAMA
MRNA icon

Nikko Asset Management Americas’s Moderna MRNA Stock Holding History

Nikko Asset Management Americas’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-850,035
Closed -$56.8M – 187
2024
Q3 		$56.8M Buy
850,035
+148,986
+21% +$13.7M 0.64% 40
2024
Q2 		$83.2M Sell
701,049
-40,734
-5% -$5.15M 0.96% 28
2024
Q1 		$79M Buy
741,783
+453,004
+157% +$45.7M 0.78% 35
2023
Q4 		$28.7M Buy
288,779
+163,607
+131% +$13.8M 0.28% 60
2023
Q3 		$12.9M Buy
125,172
+102,285
+447% +$11.4M 0.15% 76
2023
Q2 		$2.78M Buy
22,887
+901
+4% +$120K 0.03% 135
2023
Q1 		$3.34M Sell
21,986
-1,624
-7% -$268K 0.04% 125
2022
Q4 		$4.24M Sell
23,610
-1,776
-7% -$290K 0.06% 121
2022
Q3 		$3.01M Buy
25,386
+96
+0.4% +$14.6K 0.04% 133
2022
Q2 		$3.59M Buy
+25,290
New +$3.61M 0.04% 132

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Nikko Asset Management Americas's MRNA Position: Q4 2024 in Review

Nikko Asset Management Americas sold out of Moderna (MRNA) in Q4 2024, closing a stake of 850,035 shares — an estimated $56.8M sold.

Nikko Asset Management Americas first reported a position in MRNA in Q2 2022 and held it in 10 quarters. The position peaked at $83.2M in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Nikko Asset Management Americas reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Nikko Asset Management Americas sold 850,035 Moderna shares in Q4 2024, an estimated $56.8M.
  • Nikko Asset Management Americas first reported a position in Moderna in Q2 2022 and held it in 10 quarters.
  • Nikko Asset Management Americas's Moderna position peaked at $83.2M in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Nikko Asset Management Americas's 13F filing for Q4 2024, filed 10 Feb 2025.